As of Friday, January 23, Molecular Partners AG’s MOLN share price has surged by 6.99%, which has investors questioning if ...
Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing ...
Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Spare a thought for those who held Molecular Partners AG (VTX:MOLN) for five whole years - as the share ...
Every investor in Molecular Partners AG (VTX:MOLN) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 50% to be precise, is ...
Fintel on MSN
HC Wainwright & Co. initiates coverage of Molecular Partners AG - Depositary Receipt (MOLN) with buy recommendation
Fintel reports that on January 27, 2026, HC Wainwright & Co. initiated coverage of Molecular Partners AG - Depositary Receipt ...
Leerink Partners analyst Jonathan Chang maintained a Buy rating on Molecular Partners (MOLN – Research Report) on October 22. The company’s shares opened today at $6.24. According to TipRanks, Chang ...
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
MOLN is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of MOLN shares has increased $0.06 since the market last closed. This is a 1.47% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results